Involuntary 5F-ADB-related intoxication following e-cigarette use.


Journal

International journal of legal medicine
ISSN: 1437-1596
Titre abrégé: Int J Legal Med
Pays: Germany
ID NLM: 9101456

Informations de publication

Date de publication:
Jul 2021
Historique:
received: 20 11 2020
accepted: 03 03 2021
pubmed: 26 3 2021
medline: 25 9 2021
entrez: 25 3 2021
Statut: ppublish

Résumé

The detection of synthetic cannabinoid (SC) intoxication cases is challenging, even more when the involved SC identification is requested in a forensic context. This situation can be complicated by new modes of SC consumption, non-specific symptomatology, and analytical pitfalls. To illustrate these issues, we report the case of a 16-year-old man who presented symptoms evocating of a seizure disorder in the minutes following the use of a friend's e-cigarette. At admission in the emergency department, his electroencephalogram was interpreted as coherent with a recent seizure episode. 5F-ADB, a third generation SC, was detected in the e-liquid and in an early collected (H2 after the e-cigarette use) serum sample (0.50 µg/L), but not in urine samples (H18 and H38). One 5F-ADB metabolite, O-desmethyl-5F-ADB (M5), was detectable in urine up to at least 38 h after intoxication. Neither 5F-ADB nor its metabolites could be detected in victim's hair sampled 3 months after the intoxication. Although leading to a non-specific symptomatology, acute SC intoxication should be considered when the case history is related to e-cigarette or e-liquid use. Early biological samples are recommended, even if analytical screening can be positive for SC metabolites in urine sampled until 2 days after exposure. Accordingly, data from the literature and the present case underscore the relevance of adding both main 5F-ADB metabolites (M5 and 5-OH-pentyl-ADB) to mass spectrum databases used for toxicological screening in order to reduce the risk of false-negative results in intoxication cases involving 5F-ADB.

Identifiants

pubmed: 33765158
doi: 10.1007/s00414-021-02561-8
pii: 10.1007/s00414-021-02561-8
doi:

Substances chimiques

Cannabinoids 0
Synthetic Drugs 0
5F-ADB cannabinoid UN52BPP7RB

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1467-1470

Références

Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D (2017) Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther 101(2):220–229. https://doi.org/10.1002/cpt.563
doi: 10.1002/cpt.563 pubmed: 27861784
Trecki J, Gerona RR, Schwartz MD (2015) Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373(2):103–107. https://doi.org/10.1056/NEJMp1505328
doi: 10.1056/NEJMp1505328 pubmed: 26154784
Lam RPK, Tang MHY, Leung SC, Chong YK, Tsui MSH, Mak TWL (2017) Supraventricular tachycardia and acute confusion following ingestion of e-cigarette fluid containing AB-FUBINACA and ADB-FUBINACA: a case report with quantitative analysis of serum drug concentrations. Clin Toxicol (Phila) 55(7):662–667. https://doi.org/10.1080/15563650.2017.1307385
doi: 10.1080/15563650.2017.1307385
Gaulier JM, Richeval C, Phanithavong M, Brault S, Allorge D, Dumestre-Toulet V (2019) A case report of carfentanil-related fatality in France. Toxicol Anal Clin 31(4):323–331. https://doi.org/10.1016/j.toxac.2019.01.002
doi: 10.1016/j.toxac.2019.01.002
Presley BC, Castaneto MS, Logan BK, Jansen-Varnum SA (2020) Metabolic profiling of synthetic cannabinoid 5F-ADB and identification of metabolites in authentic human blood samples via human liver microsome incubation and ultra-high-performance liquid chromatography/high-resolution mass spectrometry. Rapid Commun Mass Spectrom 34(22):e8908. https://doi.org/10.1002/rcm.8908
doi: 10.1002/rcm.8908 pubmed: 32710798
Usui K, Fujita Y, Kamijo Y, Kokaji T, Funayama M (2018) Identification of 5-Fluoro ADB in Human Whole Blood in Four Death Cases. J Anal Toxicol 42(2):e21–e25. https://doi.org/10.1093/jat/bkx088
doi: 10.1093/jat/bkx088 pubmed: 29186561
Angerer V, Jacobi S, Franz F, Auwärter V, Pietsch J (2017) Three fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA. Forensic Sci Int 281:e9–e15. https://doi.org/10.1016/j.forsciint.2017.10.042
doi: 10.1016/j.forsciint.2017.10.042 pubmed: 29133010
McCain KR, Jones JO, Chilbert KT, Patton AL, James LP, Moran JH (2018) Impaired driving associated with the synthetic cannabinoid 5F-ADB. J Forensic Sci Criminol 6(1): https://doi.org/10.15744/2348-9804.6.105 .
Barceló B, Pichini S, López-Corominas V, Gomila I, Yates C, Busardò FP, Pellegrini M (2017) Acute intoxication caused by synthetic cannabinoids 5F-ADB and MMB-2201: a case series. Forensic Sci Int 273:e10–e14. https://doi.org/10.1016/j.forsciint.2017.01.020
doi: 10.1016/j.forsciint.2017.01.020 pubmed: 28190538
Kraemer M, Fels H, Dame T, Musshoff F, Halter S, Mogler L, Hess C, Madea B, Maas A (2019) Mono-/polyintoxication with 5F-ADB: a case series. Forensic Sci Int 301:e29–e37. https://doi.org/10.1016/j.forsciint.2019.05.017
doi: 10.1016/j.forsciint.2019.05.017 pubmed: 31138461
Yeter O, Ozturk YE (2019) Metabolic profiling of synthetic cannabinoid 5F-ADB by human liver microsome incubations and urine samples using high-resolution mass spectrometry. Drug Test Anal 11(6):847–858. https://doi.org/10.1002/dta.2566
doi: 10.1002/dta.2566 pubmed: 30610752
United Nations Office on Drugs and Crime (2020) Current NPS Threats Volume II. https://www.unodc.org/documents/scientific/Current_NPS_Threats_Volume_II_Web.pdf . Accessed 18 Nov 2020
Elamin M, Dunn M, Dargan PI, Wood DM, Tucker S, Hill SL, Thomas SHL (2017) Clinical features following analytically confirmed use of 5F-ADB, a synthetic cannabinoid receptor agonist. A report from the UK IONA study. Clinical Toxicology 37th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 16–19 May 2017, Basel, Switzerland (poster#163):73–74. https://doi.org/10.1080/15563650.2017.1309792 .
Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, Mack JB, Glass M, McGregor IS, Connor M, Kassiou M (2016) Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and their analogues. ACS Chem Neurosci 7(9):1241–1254. https://doi.org/10.1021/acschemneuro.6b00137
doi: 10.1021/acschemneuro.6b00137 pubmed: 27421060
Franz F, Jechle H, Angerer V, Pegoro M, Auwärter V, Neukamm MA (2018) Synthetic cannabinoids in hair - pragmatic approach for method updates, compound prevalences and concentration ranges in authentic hair samples. Anal Chim Acta 1006:61–73. https://doi.org/10.1016/j.aca.2017.12.029
doi: 10.1016/j.aca.2017.12.029 pubmed: 30016265
Lagoutte-Renosi J, Richeval C, Phanithavong M, Wiart JF, Castex E, Vanhoy X, Hakim F, Deheul S, Tournebize J, Allorge D, Gaulier JM (2020) Hair analysis can support the follow-up addiction care after acute new psychoactive substances intoxication: illustration by two cases. Drug Test Anal. https://doi.org/10.1002/dta.2936
doi: 10.1002/dta.2936 pubmed: 33140585
Franz F, Angerer V, Hermanns-Clausen M, Auwärter V, Moosmann B (2016) Metabolites of synthetic cannabinoids in hair–proof of consumption or false friends for interpretation? Anal Bioanal Chem 408(13):3445–3452. https://doi.org/10.1007/s00216-016-9422-2
doi: 10.1007/s00216-016-9422-2 pubmed: 26935933

Auteurs

Sophie Salle (S)

CHU Lille, Unité Fonctionnelle de Toxicologie, F-59000, Lille, France.
Direction Centrale du Service de Santé Des Armées, F-75017, Paris, France.
Paris University, INSERM UMRS-1144, F-75006, Paris, France.

Christelle Sevestre (C)

Service de Pédiatrie, CH D'Avranches-Granville, F-50300, Avranches, France.

Camille Richeval (C)

CHU Lille, Unité Fonctionnelle de Toxicologie, F-59000, Lille, France.
Univ. Lille, ULR 4483 - IMPECS - IMPact de L'Environnement Chimique Sur La Santé Humaine, F-59000, Lille, France.

Florian Hakim (F)

CHU Lille, Unité Fonctionnelle de Toxicologie, F-59000, Lille, France.
Univ. Lille, ULR 4483 - IMPECS - IMPact de L'Environnement Chimique Sur La Santé Humaine, F-59000, Lille, France.

Delphine Allorge (D)

CHU Lille, Unité Fonctionnelle de Toxicologie, F-59000, Lille, France.
Univ. Lille, ULR 4483 - IMPECS - IMPact de L'Environnement Chimique Sur La Santé Humaine, F-59000, Lille, France.

Jean-Michel Gaulier (JM)

CHU Lille, Unité Fonctionnelle de Toxicologie, F-59000, Lille, France. jean-michel.gaulier@chru-lille.fr.
Univ. Lille, ULR 4483 - IMPECS - IMPact de L'Environnement Chimique Sur La Santé Humaine, F-59000, Lille, France. jean-michel.gaulier@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH